KMDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kamada Ltd (KMDA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has achieved a positive milestone with FDA approval for its plasma collection center, the technical indicators and financial performance do not strongly support an immediate investment. The stock is currently in a neutral technical position, with no significant trading signals or strong upward momentum. Additionally, the financials show mixed results, with revenue growth but declining net income and gross margin.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 26.49, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 8.166), with resistance at R1: 8.915. Overall, the technical indicators suggest a neutral trend.
FDA approval for the San Antonio plasma collection center, which enhances Kamada's competitive position in the U.S. plasma market.
Stock trend analysis indicates a 60% probability of a price decline in the short term (-0.61% in the next day, -2.37% in the next week, and -5.52% in the next month). Weak gross margin and net income performance in the latest quarter.
In 2025/Q4, revenue increased by 14.54% YoY to $44.68M, but net income dropped by 6.46% YoY to $3.56M. EPS remained flat at 0.06, and gross margin declined significantly by 13.01% YoY to 37.98%.
No recent analyst ratings or price target changes available.
